Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26458482
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Indian+J+Ophthalmol
2015 ; 63
(7
): 616-8
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Intravitreal aflibercept for management of subfoveal choroidal neovascularization
secondary to angioid streaks
#MMPMID26458482
Esen E
; Sizmaz S
; Demircan N
Indian J Ophthalmol
2015[Jul]; 63
(7
): 616-8
PMID26458482
show ga
In this study, we reported the clinical results of switching from ranibizumab to
aflibercept for the treatment of an insufficient responder with choroidal
neovascularization (CNV) secondary to angioid streaks (AS). A 39-year-old female
patient with CNV secondary to AS had bilateral persistent intraretinal and
subretinal fluid on the optical coherence tomography despite prior intravitreal
0.5 mg ranibizumab injections. The therapy was switched to intravitreal injection
of aflibercept. The patient received a loading dose of three intravitreal 2 mg
aflibercept injections at 4-week intervals for both eyes. Morphological and
functional effects were observed as early as 1-week after the first injection.
After the third aflibercept injection, her visual acuity improved, intraretinal
and subretinal fluid resolved, and central macular thickness reduced in both
eyes. This is an early, but encouraging and promising result indicating that
aflibercept might be a good alternative management for CNV secondary to AS that
is insufficiently responding to prior ranibizumab injections.